Please use this identifier to cite or link to this item:
https://hdl.handle.net/11499/46865
Title: | Bosutinib-induced massive pleural effusion: Cross-intolerance with all tyrosine kinase inhibitors | Authors: | Aslan, Nevin Alayvaz Hincal, Hande Ogul Elver, Ozde Erol, Veysel Guler, Nil |
Keywords: | Bosutinib pleural effusion cross-intolerance chronic myeloid leukemia Chronic Myeloid-Leukemia Imatinib Safety Hypertension Resistance Efficacy |
Publisher: | Sage Publications Ltd | Abstract: | Background: The discovery of tyrosine kinase inhibitors provided a breakthrough in the treatment of chronic myeloid leukemia. Nowadays, the management of tyrosine kinase inhibitor-related side effects is one of the important problems in chronic myeloid leukemia treatment. Grades 3-4 pulmonary toxicity; especially pleural effusion is mostly seen with dasatinib treatment but rarely seen with nilotinib and bosutinib. Development of cross-intolerance due to pleural effusion is not an expected situation. Pleural effusion related to tyrosine kinase inhibitors is mostly exudative in nature with abundant lymphocytes. Case report: Massive pleural effusion developed in a 59-year-old male patient with chronic myeloid leukemia, who was being treated with bosutinib. In the past, the patient had experienced massive pleural effusion also with dasatinib and nilotinib. The evaluation for differential diagnosis of pleural effusion did not reveal any additional malignancy. Management and outcome: After discontinuation of bosutinib and initiation of prednisolone, pleural effusion was totally resolved. Prednisolone was gradually discontinued and third-generation tyrosine kinase inhibitor ponatinib was started. After 12 months of follow-up, massive pleural effusion occurred again, leading to discontinuation of ponatinib. Discussion: Cross-intolerance is an important problem in the tyrosine kinase inhibitor era. The significance of this case is the development of cross-intolerance to all second-generation tyrosine kinase inhibitors and furthermore to a third-generation tyrosine kinase inhibitor. Management strategies for pleural effusion and close follow-up are important. | Description: | Article; Early Access | URI: | https://doi.org/10.1177/10781552221114070 https://hdl.handle.net/11499/46865 |
ISSN: | 1078-1552 1477-092X |
Appears in Collections: | PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection Tıp Fakültesi Koleksiyonu WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection |
Show full item record
CORE Recommender
SCOPUSTM
Citations
2
checked on Oct 13, 2024
WEB OF SCIENCETM
Citations
3
checked on Oct 22, 2024
Page view(s)
60
checked on Aug 24, 2024
Google ScholarTM
Check
Altmetric
Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.